Efficacy Remains the Major Hurdle
AI-first pipelines has yet to deliver compounds that surpass the Phase 2 efficacy thresholds, despite the early enthusiasm and substantial investment they attracted.
AI-Rewired In-Licensing Strategy
To unlock earlier confidence in viable therapeutics and eliminate sunk costs from false candidates, we are building a predictive engine to reprogram the preclinical-to-clinical transition.
Powered by leading-edge algorithms, our engine simulates clinical efficacy and enables confident pre-trial assessment of pipeline value for in-licensing decisions.
Let us know if early access is in need! We are primed to deliver it ahead of time.
